Videos

This segment of the May episode of The Medical Sisterhood highlights the importance of addressing patients' and parents' fears in dermatology.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

Heather Johnson, MD, discusses progress in providing more individualized care to female cardiovascular patients, as well as what remains to be done.

Igor Barjaktarevic, MD, discussed findings at ATS 2026, where the recombinant therapy outperformed weekly plasma-derived augmentation on key pharmacokinetic endpoints.

In a recent episode of The Medical Sisterhood podcast, Lisa Swanson, MD, spoke about the importance of female mentorship in medicine.

Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.

This episode covers Abbott’s Libre Duo and Libre Duo 10 Day systems, Eli Lilly’s retatrutide, and the recent Dexcom sensor theft.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.

This segment of the latest Skin of Color Savvy podcast highlighted persistent disparities in skin cancer prevention, awareness, and diagnosis.

Ferdinand shares his advice on high blood pressure management, drawing on his perspective as co-author of the ACC/AHA 2025 hypertension guidelines.

At ATS 2026, Krunal Patel, MD, discussed early real-world data suggesting sotatercept may improve hemodynamics, RV remodeling, and functional outcomes in group 3 CLD-PH.

Brittany Duchene, MD, found that depressive symptoms were associated with twice the odds of poorly controlled asthma.

A quantitative CT-based approach may help predict pneumothorax risk after bronchoscopic lung volume reduction, according to findings presented at ATS 2026.

Jason Guichard, MD, PhD, lead author of the study, discusses positive 2-year data from the investigative trial of the Cordella Pulmonary Artery Sensor System.

ATS 2026 data presented by Jamey Moore, DO, suggest greater upfront corticosteroid dosing may shorten hospitalization in acute exacerbations of autoimmune-related ILD.

Freed outlines which patients should proceed directly to IV iron without a trial of oral therapy and why oral iron follow-up is inadequately practiced in the United States.

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.

This episode highlights the importance of closing persistent gaps in skin cancer prevention and awareness for patients with skin of color.

Freed discusses how to select among IV iron formulations based on practical and access considerations.

This interview highlights recent phase 3b data from the TOGETHER-PsO trial on ixekizumab and tirzepatide for psoriasis and obesity or overweight.

Miedema highlights the shortcomings of current technology and medication for what is among the US’s fastest-growing and most devastating conditions.

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.

Ashkan Shoamanesh, MD, discusses a series of abstracts presented at ESOC 2026 reinforcing asundexian’s protective effect in patients at risk of ischemic stroke or TIA.

Joshua Barrios, PhD, and Geoffrey Tison, MD, MSc, discuss their new AI echo’s comparative superiority in identifying cardiovascular disease.

Wilcox discusses the recent HFSA statement aiming to identify the unique characteristics of HFmrEF and define an alternative treatment pathway.

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

At ATS, Klaus Friedrich Rabe, MD, PhD, discussed phase 3 data on itepekimab in former smokers with chronic obstructive pulmonary disease (COPD).

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover more of the upcoming news releases announced for ADA 2026.